Aldeyra Therapeutics, Inc. ALDX

ALDX Company Overview

Aldeyra Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing therapies designed to treat immune-mediated and metabolic diseases, particularly those involving inflammation and retinal disorders. The company operates within the biopharmaceutical industry and primarily concentrates on discovering and commercializing small-molecule therapies that target reactive aldehyde species (RASP), which are implicated in inflammatory and systemic disease pathways. Aldeyra’s development programs have historically focused on ophthalmology indications such as dry eye disease, allergic conjunctivitis, and retinal disease, alongside selected systemic inflammatory conditions.

The company’s primary value drivers are its clinical-stage drug candidates, intellectual property portfolio, and regulatory advancement pipeline. Key investigational assets have included reproxalap for ocular inflammatory diseases and ADX-2191 for retinal indications. Aldeyra was founded in 2004 and became publicly traded on Nasdaq under the ticker ALDX. Over time, the company evolved from an early-stage research platform into a clinical-stage biotechnology company with multiple programs evaluated in late-stage clinical trials and interactions with the U.S. Food and Drug Administration through formal regulatory submission processes documented in SEC filings and company disclosures.